top of page

One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for Hereditary Angioedema

Aug 5
4 min read

Updated: 14 hours ago

On August 6, 2026, Intellia Therapeutics reported its second-quarter results and laid out the path to market for lonvo-z (lonvoguran ziclumeran), a one-time CRISPR treatment for hereditary angioedema (HAE). The company highlighted its Phase 3 HAELO results, published in the New England Journal of Medicine, and said it expects a U.S. launch in the first half of 2027.

The numbers behind that confidence are striking. In HAELO, a single infusion cut HAE attacks by 87% compared with placebo. Most treated patients became attack-free without any other preventive medicine.


What it's like to live with HAE

HAE is a rare genetic disorder that causes sudden, severe swelling attacks. They can strike the hands, feet, face, gut, and airway. Abdominal attacks can be intensely painful and are sometimes mistaken for surgical emergencies. Swelling in the throat can be life-threatening.

Attacks are unpredictable. Many patients live with constant uncertainty, carry emergency medication everywhere, and take preventive treatments that may require regular injections or infusions, sometimes as often as every few days.

The cause, in most cases, is a shortage of a protein called C1 inhibitor. Without enough of it, a pathway involving the enzyme kallikrein runs out of control and produces too much bradykinin, a molecule that makes blood vessels leak fluid into tissue. That leakage is the swelling.


How lonvo-z works: switch off the source

IV infusion bag releasing lipid nanoparticles that travel through the bloodstream into liver cells

Lonvo-z doesn't replace C1 inhibitor. It goes one step upstream.

The liver makes prekallikrein, the precursor of kallikrein, from a gene called KLKB1. Lonvo-z uses CRISPR-Cas9 to cut and permanently disable KLKB1 in liver cells. Less prekallikrein means less kallikrein, less bradykinin, and fewer attacks.

This is in vivo editing, meaning the edit happens inside the body. The CRISPR instructions (an mRNA for the Cas9 enzyme plus a guide RNA) travel in a lipid nanoparticle, which hepatocytes take up efficiently. After a single IV infusion, the edit is made in the patient's own liver cells and is meant to last.

Because the edit is made in the DNA of hepatocytes, the reduction in prekallikrein is intended to be permanent after a single dose.


The Phase 3 results

HAELO was a randomized, double-blind, placebo-controlled trial. It enrolled 80 patients: 52 received lonvo-z and 28 received placebo. Topline results were announced on April 27, 2026, with fuller data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in June.

  • Primary endpoint: Mean monthly attacks fell to 0.26 with lonvo-z versus 2.10 with placebo, an 87% reduction (p < 0.0001).

  • Attack-free and off prophylaxis: 62% of treated patients had no attacks and needed no preventive medicine, compared with 11% on placebo.

  • Safety: No serious adverse events during the primary observation period. The most common side effects were mild-to-moderate infusion-related reactions, headache, and fatigue.

One design detail makes the results more impressive. Patients stopped their existing preventive treatment before receiving lonvo-z. Investigators described this as a "higher bar to meet," since the therapy had to work entirely on its own.

Earlier Phase 1/2 data pointed the same way. In that study, patients saw a 95% mean reduction in monthly attacks, and 93% stayed attack-free and off prophylaxis, with some followed for up to two years.


Why this is a landmark

It's the strongest evidence yet for in vivo CRISPR. Casgevy, the first approved CRISPR therapy, edits cells outside the body and requires chemotherapy. Lonvo-z is a single infusion, with no cell collection and no conditioning. A large, placebo-controlled Phase 3 success is exactly what the field needed to show in vivo editing can work at scale.

It could replace lifelong treatment. For patients who inject or infuse preventive medicine regularly, a one-time treatment could be life-changing. It could also change the economics of HAE care over a lifetime.

It supports the liver as a target organ. Lipid nanoparticles naturally accumulate in the liver. That makes liver-made proteins, including prekallikrein, PCSK9, and alpha-1 antitrypsin, some of the most practical targets for in vivo editing.


What to keep in mind

Permanent edits carry permanent questions. Long-term follow-up will need to confirm the effect lasts and watch for any late safety signals. Researchers will also keep studying off-target editing, meaning unintended cuts elsewhere in the genome. Price and access will matter too, since HAE already has several effective, if burdensome, preventive treatments.


The bottom line

One infusion, and most patients in HAELO stopped having attacks. Lonvo-z has now shown in a rigorous Phase 3 trial what in vivo CRISPR editing can do. Intellia's next step, the regulatory filing, came just weeks later.

Keep exploring with Gene Tech Times

  • Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.

  • Go deeper: In-Depth Molecular Biology covers CRISPR, transcription, translation and DNA repair at college level, self-paced.

  • Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.

  • Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.

— T.N., Gene Tech Times

Comments


Subscribe for News

bottom of page